Refs400-499

Nanomedicine, Volume IIA: Biocompatibility

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003

References 400-499

400. Y. Okura, R. Tanaka, K. Ono, S. Yoshida, N. Tanuma, Y. Matsumoto, “Treatment of rat hemiparkinson model with xenogeneic neural transplantation: tolerance induction by anti-T-cell antibodies,” J. Neurosci. Res. 48(1 June 1997):385-396.

401. F. Zipp, M. Kerschensteiner, K. Dornmair, J. Malotka, S. Schmidt, A. Bender, G. Giegerich, R. de Waal Malefyt, H. Wekerle, R. Hohlfeld, “Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis,” Brain 121(August 1998):1395-1407.

402. W.J. Wall, “Use of antilymphocyte induction therapy in liver transplantation,” Liver Transpl. Surg. 5(July 1999):S64-S70.

403. John W. Kimball, Introduction to Immunology, Third Edition, Macmillan Publishing Company, New York, 1990.

404. M.L. Alegre, D.J. Lenschow, J.A. Bluestone, “Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors,” Dig. Dis. Sci. 40(January 1995):58-64.

405. M.S. Cole, K.E. Stellrecht, J.D. Shi, M. Homola, D.H. Hsu, C. Anasetti, M. Vasquez, J.Y. Tso, “HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro,” Transplantation 68(27 August 1999):563-571.

406. J. Gratiot-Deans, L.A. Turka, “New biologic immunosuppressive agents in transplantation,” Curr. Opin. Nephrol. Hypertens. 3(November 1994):596-601.

407. M.H. Sayegh, L.A. Turka. “T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction,” J. Am. Soc. Nephrol. 6(October 1995):1143-1150.

408. H. Matsue, K. Matsue, M. Walters, K. Okumura, H. Yagita, A. Takashima, “Induction of antigen-specific immunosuppression by CD95L cDNA-transfected ‘killer’ dendritic cells,” Nat. Med. 5(August 1999):930-937.

409. W. Fecke, T.C. Farries, L.G. D’Cruz, C.M. Napper, R.A. Harrison, “Expression of factor I-resistant mutants of the human complement component C3 in heterologous systems,” Xenotransplantation 5(February 1998):29-34.

410. B. Charlton, H. Auchincloss Jr., C.G. Fathman, “Mechanisms of transplantation tolerance,” Annu. Rev. Immunol. 12(1994):707-734.

411. L. Chatenoud, “Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity,” Mol. Med. Today 4(January 1998):25-30.

412. I. Ferber, G. Schonrich, J. Schenkel, A.L. Mellor, G.J. Hammerling, B. Arnold, “Levels of peripheral T cell tolerance induced by different doses of tolerogen,” Science 263(4 February 1994):674-676.

413. S. Aradhye, L.A. Turka, “Will tolerance become a clinical reality?” Am. J. Med. Sci. 313(May 1997):310-314.

414. S. Ehl, P. Aichele, H. Ramseier, W. Barchet, J. Hombach, H. Pircher, H. Hengartner, R.M. Zinkernagel, “Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection,” Nat. Med. 4(September 1998):1015-1019.

415. J.A. Bradley, “The blood transfusion effect: experimental aspects,” Immunol. Lett. 29(July 1991):127-132.

416. M. Ghio, P. Contini, C. Mazzei, S. Brenci, G. Barberis, G. Filaci, F. Indiveri, F. Puppo, “Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions,” Blood 93(1 March 1999):1770-1777.

417. L. Yang, B. Du Temple, Q. Khan, L. Zhang, “Mechanisms of long-term donor-specific allograft survival induced by pretransplant infusion of lymphocytes,” Blood 91(1 January 1998):324-330.

418. T. Tanigawa, M. Gotoh, H. Nagano, H. Ota, T. Fukuzaki, M. Sakon, M. Monden, “Injection of mitomycin-C-treated spleen cells induces donor-specific unresponsiveness to cardiac allografts in rats,” Transplantation 67(15 March 1999):653-658.

419. L. Frasca, P. Carmichael, R. Lechler, G. Lombardi, “Anergic T cells effect linked suppression,” Eur. J. Immunol. 27(December 1997):3191-3197.

420. M.D. Scott, K.L. Murad, “Cellular camouflage: fooling the immune system with polymers,” Curr. Pharm. Des. 4(December 1998):423-438.

421. M.D. Scott, K.L. Murad, F. Koumpouras, M. Talbot, J.W. Eaton, “Chemical camouflage of antigenic determinants: stealth erythrocytes,” Proc. Natl. Acad. Sci. (USA) 94(8 July 1997):7566-7571.

422. K.L. Murad, K.L. Mahany, C. Brugnara, F.A. Kuypers, J.W. Eaton, M.D. Scott, “Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly(ethylene glycol),” Blood 93(15 March 1999):2121-2127.

423. K.L. Murad, E.J. Gosselin, J.W. Eaton, M.D. Scott, “Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification,” Blood 94(15 September 1999):2135-2141.

424. K.M. Stuhlmeier, Y. Lin, “Camouflaging endothelial cells: does it prolong graft survival?” Biochim. Biophys. Acta. 1428(5 August 1999):177-190.

425. J.R. Head, W.B. Neaves, R.E. Billingham, “Immune privilege in the testis. I. Basic parameters of allograft survival,” Transplantation 36(October 1983):423-431.

426. H. Jahr, H. Wolff, “The liver – an immunologically privileged organ]?” Allerg. Immunol. (Leipz.) 35(1989):155-166. In German.

427. S. Maddocks, B.P. Setchell, “Recent evidence for immune privilege in the testis,” J. Reprod. Immunol. 18(August 1990):9-18.

428. J. Mokry, “Transplantation immunology of the brain as a privileged site for neural grafting,” Sb. Ved. Pr. Lek. Fak. Karlovy Univerzity Hradci Kralove 35(1992):307-326.

429. T.E. Starzl, A.J. Demetris, A.S. Rao, A.W. Thomson, M. Trucco, N. Murase, “Migratory nonparenchymal cells after organ allotransplantation: with particular reference to chimerism and the liver,” Prog. Liver Dis. 12(1994):191-213.

430. J.W. Streilein, “Peripheral tolerance induction: lessons from immune privileged sites and tissues,” Transplant Proc. 28(August 1996):2066-2070.

431. T.A. Ferguson, T.S. Griffith, “A vision of cell death: insights into immune privilege,” Immunol. Rev. 156(April 1997):167-184.

432. M.K. Matyszak, “Inflammation in the CNS: Balance between immunological privilege and immune responses,” Prog. Neurobiol. 56(October 1998):19-35.

433. F.A. Cabestre, S. Lefebvre, P. Moreau, N. Rouas-Friess, J. Dausset, E.D. Carosella, P. Paul, “HLA-G expression: immune privilege for tumour cells?” Semin. Cancer Biol. 9(February 1999):27-36.

434. J.W. Streilein, “Immunologic privilege of the eye,” Springer Semin. Immunopathol. 21(1999):95-111.

435. J.C. Van Dooremaal, Albrecht von Graefe’s Arch. Clin. Exp. Ophthalmol. 19(1873):359 et seq.

436. P.B. Medawar, “Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye,” Br. J. Exp. Pathol. 29(1948):58-69.

437. H.J. Kaplan, J.W. Streilein, “Immune response to immunization via the anterior chamber of the eye. I. F. lymphocyte-induced immune deviation,” J. Immunol. 118(March 1977):809-814.

438. W.B. Neaves, R.E. Billingham, “The lymphatic drainage of the rat prostate and its status as an immunologically privileged site,” Transplantation 27(February 1979):127-132.

439. J. Wayne Streilein, “Unraveling Immune Privilege,” Science 270(17 November 1995):1158-1159.

440. Thomas S. Griffith, Thomas Brunner, Sharon M. Fletcher, Douglas R. Green, Thomas A. Ferguson, “Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege,” Science 270(17 November 1995):1189-1192.

441. J.Y. Niederkorn, J.W. Streilein, “Intracamerally induced concomitant immunity: Mice harboring progressively growing intraocular tunors are immune to spontaneous metastases and secondary tunor challenge,” J. Immunol. 131(November 1983):2587-2594.

442. S.S. Atherton, G.A. Pesicka, J.W. Streilein, “Retinitis and deviant immune responses following intravitreal inoculation of HSV-1,” Invest. Ophthalmol. Visual Sci. 28(May 1987):859-866.

443. T. Suda, T. Takahashi, P. Golstein, S. Nagata, “Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family,” Cell 75(17 December 1993):1169-1178.

444. T. Suda, T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki, K. Nakao, S. Nagata, “Expression of the Fas ligand in cells of T cell lineage,” J. Immunol. 154(15 April 1995):3806-3813.

445. H.J. Kaplan, J.W. Streilein, “Do immunologically privileged sites require a functioning spleen?” Nature 251(11 October 1974):553-554.

446. J.W. Streilein, “Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye,” Eye 9(1995):236-240.

447. G.A. Wilbanks, J.W. Streilein, “Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood,” J. Immunol. 146(15 April 1991):2610-2617.

448. A.W. Taylor, J.W. Streilein, “Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor,” J. Immunol. 153(1 August 1994):1080-1086.

449. T.A. Ferguson, S. Fletcher, J. Herndon, T.S. Griffith, “Neuropeptides modulate immune deviation induced via the anterior chamber of the eye,” J. Immunol. 155(15 August 1995):1746-1756.

450. K. Shimada, “The complement components and their inactivators in the intraocular fluids of the guinea pig,” Invest. Ophthalmol. Visual Sci. 9(April 1970):307-315.

451. N.S. Bora, C.L. Gobleman, J.P. Atkinson, J.S. Pepose, H.J. Kaplan, “Differential expression of the complement proteins in the human eye,” Invest. Ophthalmol. Visual Sci. 34(December 1993):3579-3584.

452. J.W. Streilein, J.Y. Niederkorn, J.A. Shadduck, “Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens,” J. Exp. Med. 152(1 October 1980):1121-1125.

453. J.Y. Niederkorn, J.W. Streilein, “Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses,” J. Immunol. 131(December 1983):2670-2674.

454. J.W. Streilein, “Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments,” Curr. Opin. Immunol. 5(June 1993):428-432.

455. J.W. Streilein, M. Takeuchi, A.W. Taylor, “Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity,” Hum. Immunol. 52(February 1997):138-143.

456. D. Bellgrau, D. Gold, H. Selawry, J. Moore, A. Franzusoff, R.C. Duke, “A role for CD95 ligand in preventing graft rejection,” Nature 377(19 October 1995):630-632; see erratum at Nature 394(9 July 1998):133.

457. Jian-Jun Chen, Yongnian Sun, Gary J. Nabel, “Regulation of the proinflammatory effects of Fas ligand (CD95L),” Science 282(27 November 1998):1714-1717; http://www.sciencemag.org/cgi/content/full/282/5394/1714

458. J. Dhein, H. Walczak, C. Baumler, K.M. Debatin, P.H. Krammer, “Autocrine T-cell suicide mediated by APO-1,” Nature 373(2 February 1995):438-441.

459. T. Brunner, R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, et al, “Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas,” Nature 373(2 February 1995):441-444.

460. S.T. Ju, D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, A. Marshak-Rothstein, “Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation,” Nature 373(2 February 1995):444-448.

461. S. Nagata, P. Golstein, “The Fas death factor,” Science 267(10 March 1995):1449-1456.

462. P. Le Bouteiller, C. Solier, J. Proll, M. Aguerre-Girr, S. Fournel, F. Lenfant, “Placental HLA-G protein expression in vivo: where and what for?” Hum. Reprod. Update 5(May-June 1999):223-233.

463. S.C. Spencer, J.W. Fabre, “Bulk purification of a naturally occuring soluble form of RT1 – A class I major histocompatibility complex antigen from DA rat liver, and studies of specific immunosuppression,” Transplantation 44(July 1987):141-148.

464. P. Hooper, N.S. Bora, H.J. Kaplan, T.A. Ferguson, “Inhibition of lymphocyte proliferation by resident ocular cells,” Curr. Eye Res. 10(April 1991):363-372.

465. G.A. Wilbanks, M. Mammolenti, J.W. Streilein, “Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta,” Eur. J. Immunol. 22(January 1992):165-173.

466. P.T. Khaw, G.S. Schultz, S.L. MacKay, N. Chegini, D.S. Rotatori, J.L. Adams, R.W. Shimizu, “Detection of transforming growth factor-alpha messenger RNA and protein in human corneal epithelial cells,” Invest. Ophthalmol. Visual Sci. 33(November 1992):3302-3306.

467. S.L. Schor, I. Ellis, C.R. Irwin, J. Banyard, K. Seneviratne, C. Dolman, A.D. Gilbert, D.M. Chisholm, “Subpopulations of fetal-like gingival fibroblasts: characterisation and potential significance for wound healing and the progression of periodontal disease,” Oral Dis. 2(June 1996):155-166.

468. David H. Munn, Min Zhou, John T. Attwood, Igor Bondarev, Simon J. Conway, Brendan Marshall, Corrie Brown, Andrew L. Mellor, “Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism,” Science 281(21 August 1998):1191-1193.

469. D.H. Munn, E. Armstrong, “Cytokine regulation of human monocyte differentiation in vitro: the tunor-cytotoxic phenotype induced by macrophage colony-stimulating factor is developmentally regulated by gamma-interferon,” Cancer Res. 53(1 June 1993):2603-2613.

470. D.H. Munn, J. Pressey, A.C. Beall, R. Hudes, M.R. Alderson, “Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion,” J. Immunol. 156(15 January 1996):523-532.

471. D.H. Munn, E. Shafizadeh, J.T. Attwood, I. Bondarev, A. Pashine, A.L. Mellor, “Inhibition of T cell proliferation by macrophage tryptophan catabolism,” J. Exp. Med. 189(3 May 1999):1363-1372.

472. R.R.H. Coombs, A. Gristina, D. Hungerford, eds., Joint Replacement – State of the Art, Orthotext, London, 1990.

473. Richard Coombs, Stephen Fewster, Gavin Pearson, “Chapter 1. Clinical Implications for Nanotechnology,” in Richard R.H. Coombs, Dennis W. Robinson, eds., Nanotechnology in Medicine and the Biosciences, Gordon and Breach Publishers, The Netherlands, 1996, pp. 3-16.

474. Stephen Fewster, Richard Coombs, Jonathan Kitson, Shun Hua Zhou, “Chapter 8. Ultrafine Texturing of Biomaterials for Cellular Adhesion,” in Richard R.H. Coombs, Dennis W. Robinson, eds., Nanotechnology in Medicine and the Biosciences, Gordon and Breach Publishers, The Netherlands, 1996, pp. 125-132.

475. S.C. Tseng, P. Prabhasawat, S.H. Lee, “Amniotic membrane transplantation for conjunctival surface reconstruction,” Am. J. Ophthalmol. 124(December 1997):765-774.

476. J. Shimazaki, N. Shinozaki, K. Tsubota, “Transplantation of amniotic membrane and limbal autograft for patients with recurrent pterygium associated with symblepharon,” Br. J. Ophthalmol. 82(March 1998):235-240.

477. S.C. Tseng, P. Prabhasawat, K. Barton, T. Gray, D. Meller, “Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency,” Arch. Ophthalmol. 116(April 1998):431-441.

478. A. Azuara-Blanco, C.T. Pillai, H.S. Dua, “Amniotic membrane transplantation for ocular surface reconstruction,” Br. J. Ophthalmol. 83(April 1999):399-402.

479. H.S. Dua, “Amniotic membrane transplantation,” Br. J. Ophthalmol. 83(June 1999):748-752.

480. M.A. Kurpakus, C. Daneshvar, J. Davenport, A. Kim, “Human corneal epithelial cell adhesion to laminins,” Curr. Eye Res. 19(August 1999):106-114.

481. F.E. Kruse, K. Rohrschneider, H.E. Volcker, “Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers,” Ophthalmology 106(August 1999):1504-1510, 1511 (discussion).

482. J.K. Burgers, R.J. Nelson, D.M. Quinlan, P.C. Walsh, “Nerve growth factor, nerve grafts and amniotic membrane grafts restore erectile function in rats,” J. Urol. 146(August 1991):463-468.

483. M. Nisolle, J. Donnez, “Vaginoplasty using amniotic membranes in cases of vaginal agenesis or after vaginectomy,” J. Gynecol. Surg. 8(Spring 1992):25-30.

484. H.O. Rennekampff, P. Dohrmann, R. Fory, F. Fandrich, “Evaluation of amniotic membrane as adhesion prophylaxis in a novel surgical gastroschisis model,” J. Invest. Surg. 7(May-June 1994):187-193.

485. T.W. Hensle, E.K. Seaman, “Vaginal reconstruction in children and adults,” Tech. Urol. 1(Winter 1995):174-180.

486. F. Cerneca, M. Andolina, R. Simeone, R. Boscolo, G. Ciana, B. Bembi, “Treatment of patients with Niemann-Pick type is using repeated amniotic epithelial cells implantation: correction of aggregation and coagulation abnormalities,” Clin. Pediatr. (Phila.) 36(March 1997):141-146.

487. R. Guler, M.T. Ercan, N. Ulutuncel, H. Devrim, N. Uran, “Measurement of blood flow by the 133Xe clearance technique to grafts of amnion used in vestibuloplasty,” Br. J. Oral Maxillofac. Surg. 35(August 1997):280-283.

488. Z. Zachariou, “Amniotic membranes as prosthetic material: experimental utilization data of a rat model,” J. Pediatr. Surg. 32(October 1997):1458-1463.

489. Anna Tafuri, Judith Alferink, Peter Moller, Gunter J. Hammerling, Bernd Arnold, “T Cell Awareness of Paternal Alloantigens During Pregnancy,” Science 270(27 October 1995):630-633.

490. W. McLeish, P. Rubsamen, S.S. Atherton, J.W. Streilein, “Immunobiology of Langerhans cells on the ocular surface. II. Role of central corneal Langerhans cells in stromal keratitis following experimental HSV-1 infection in mice,” Reg. Immunol. 2(July-August 1989):236-243.

491. Y. Sano, B.R. Ksander, J.W. Streilein, “Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction,” Invest. Ophthalmol. Visual Sci. 36(October 1995):2176-2185.

492. E.J. Pearce, A. Sher, “Mechanisms of immune evasion in schistosomiasis,” Contrib. Microbiol. Immunol. 8(1987):219-232.

493. N. Saunders, R.A. Wilson, P.S. Coulson, “The outer bilayer of the adult schistosome tegument surface has a low turnover rate in vitro and in vivo,” Mol. Biochem. Parasitol. 25(September 1987):123-131.

494. J. Modha, M.J. Doenhoff, “Schistosoma mansoni host-parasite relationship: interaction of contrapsin with adult worms,” Parasitology 109(November 1994):487-495.

495. J.E. Allen, R.M. Maizels, “Immunology of human helminth infection,” Int. Arch. Allergy Immunol. 109(January 1996):3-10.

496. J.H. McKerrow, “Cytokine induction and exploitation in schistosome infections,” Parasitology 115(1997):S107-S112.

497. J.F. Brouwers, P.J. Skelly, L.M. Van Golde, A.G. Tielens, “Studies on phospholipid turnover argue against sloughing of tegumental membranes in adult Schistosoma mansoni,” Parasitology 119(September 1999):287-294.

498. Robert S. Goldsmith, “Chapter 34. Infectious Diseases: Protozoal & Helminthic,” in Lawrence M. Tierney, Jr., Stephen J. McPhee, Maxine A. Papadakis, eds., Current Medical Diagnosis and Treatment, 35th Edition, Appleton and Lange, Stamford, CT, 1996, pp. 1246-1305.

499. K.R. Rasmussen, W.M. Kemp, “Schistosoma mansoni: interactions of adult parasites with the complement system,” Parasite Immunol. 9(March 1987):235-248.

Last updated on 16 April 2004